AN-1792: Overview

Modified on 2009/10/14 21:43 by admin
AN-1792 is an experimental Alzheimer's drug that appears to work by stimulating the immune system to "recognize" and attack the build-up of amyloid plaque, a substance believed to be characteristic of the neurological disorder. Developed in the late 1990s by pharmaceutical makers Elan Corporation and Wyeth-Ayerst Laboratories, AN-1792 initially showed great promise in rodents. Injections of the drug prevented formation of plaques in the brains of young mice. The drug showed signs of improving memory in mice already impaired by the disease. Furthermore, AN-1792 prevented Alzheimer's development in healthy mice.

The U.S. Food and Drug Administration soon approved AN-1792 for clinical trials involving humans. Recently, four patients in France developed inflammation of the central nervous system after using the drug. After the alarming development, clinical trials were immediately halted. Medical and scientific experts are currently trying to pinpoint the cause of the complication. Over 350 patients in Europe and the United States have received doses of the drug.

See Also

  1. Alzheimers & Dementia: Overview
  2. Head, Spinal Cord, Brain & Nerve Disorders: Overview
  Name Size